Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of CREG1 protein in prevention or treatment of sorafenib-induced myocardial injury

A myocardial injury, protein technology, applied in the medical use of myocardial injury and related diseases, CREG1 protein or its active fragment field

Pending Publication Date: 2021-06-08
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether CREG1 regulates sorafenib-induced myocardial injury has not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of CREG1 protein in prevention or treatment of sorafenib-induced myocardial injury
  • Medical application of CREG1 protein in prevention or treatment of sorafenib-induced myocardial injury
  • Medical application of CREG1 protein in prevention or treatment of sorafenib-induced myocardial injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0046] Example 2 Sarafini intervention induces cardiac tissue and cellular procedural death.

[0047] 1. Western blot Detects myocardial tissue procedural death protein expression.

[0048] Western blot method detection procedural death marker protein RIP3 and P-RIP3 expression. The protein concentration was measured by the RIPA lysate to extract the control group and the Solafini intervention group, and the protein concentration was determined using a BCA colorimetric kit. The expression of CREG protein was detected with Western Blot.

[0049] Specifically, the 40 μg of protein was boiled at 95 ° C for 5 min, and the hydraulic SDS-PAGE electrophoresis was separated by 10%, and the electrophoresis ended time. Samples were transferred to the cellulose membrane at 90V, and the time was 2 h; after normal temperature was closed for 2 hours in TBS-T dilution, it was added to incubate overnight at 4 ° C. The anti-RIP3 antibody (1: 1000, US ABCAM), anti-P-RIP3 antibody (1: 1000, US ABCAM...

Embodiment 3

[0058] Example 3 The expression of CREG1 in myocardial tissue in Sarafini decreased.

[0059] 1. Fluorescence Quantitative PCR Method Detects the expression of Creg1 gene mRNA in the front of the myocardial tissue before Sarafini.

[0060] The tissue RNA was extracted with a Promega kit and a TAKARA reverse transcription kit was used to obtain a reverse transcription reaction to obtain cDNA, followed by a quantitative PCR reaction with a Sybgreen method. Quantitative PCR primer sequences are as follows:

[0061]

[0062] The results showed that there was no significant change in the expression level of CREG gene mRNA in Sarafini group compared to the control group. Figure 2A Indicated.

[0063] 2, Western blot to detect the expression of CREG protein in myocardial tissue.

[0064] In order to detect the expression of CREG in myocardial tissue induced by Sarafini, CREG protein expression was detected by WesternBlot. Specific methods are shown in Example 1. The anti-CREG antibody ...

Embodiment 4

[0066]Example 4 Exogenous administration CREG recombinant protein significantly reduced C57BL / 6J mouse heart functional damage in Sarafini intervention.

[0067] 1. Exogenous CREG protein intervention is administered on the model of Sarafini-induced heart function injury.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medical application of E1A activated gene repressor protein, in particular to a medical application of CREG1 protein or an active fragment thereof in prevention and / or treatment of sorafenib-induced myocardial injury and related diseases. Experiments prove that sorafenib intervention causes decline of the heart function of a wild type C57BL / 6J mouse, meanwhile, the expression of mRNA and protein of CREG1 gene in myocardial tissue are remarkably reduced, and myocardial injury markers are remarkably increased. Exogenous administration of CREG1 recombinant protein can significantly reduce sorafenib-induced myocardial injury and cardiac dysfunction. The expression of the sorafenib-induced mouse myocardial cell programmed necrosis marker protein is obviously increased, and the death mode is programmed necrosis; exogenous administration of CREG1 recombinant protein can significantly inhibit the occurrence of programmed myocardial cell death induced by sorafenib, and the cardiac function is improved. The CREG1 recombinant protein can be used for preventing or treating myocardial injury and related diseases caused by sorafenib.

Description

Technical field [0001] The present invention relates to medical use of E1A activation gene repuggestions (CREG1) protein, which specifically involves CREG1 proteins or active fragments for preventing and / or treating Sarafini-induced myocardial injury and related diseases. Medical use. Background technique [0002] With the rapid development of clinical tumors therapy, the survival rate and the quality of survival in tumor patients have been greatly improved. However, heart toxicity caused by anti-tumor drugs also exists and cannot be ignored. In August 2016, the European Heart Society (ESC) released the first "2016esc cancer treatment and cardiovascular scientific statement" related to clinical practice, cardiovascular complications related to tumor treatment, such as myocardial function and heart failure , Coronary disease, cardiac valve disease, arrhythmia, high blood pressure, thromboembrays, surrounding vascular diseases and stroke, pulmonary hypertension and cardiac compli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P9/00C12Q1/6883G01N33/68
CPCA61K38/1709A61P9/00C12Q1/6883G01N33/6893C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158G01N2800/32G01N2333/47Y02A50/30
Inventor 韩雅玲闫承慧宋紫萍田孝祥刘丹张效林
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com